ARHGDIA and invasive breast carcinoma: In addition, Ronneburg et al. demonstrated that RhoGDI1 may sensitize invasive breast cancer to treatment with CMF (cyclophosphamide, methotrexate, and 5-fluorouracil), and higher RhoGDI1 expression tends to be correlated with a better clinical outcome [30].